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closure in high risk patients.
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BACKGROUND Percutaneous LAA closure is increasingly performed
in patients with atrial ﬁbrillation and contraindications to anti-
coagulation to lower their stroke and systemic embolism risk. The
safety and efﬁcacy of LAA closure relies on accurate device sizing,
which necessitates accurate measurement of LAA dimensions. LAA
size may change with volume status, and as patients are fasting for
these procedures, intraprocedural measurements may not be repre-
sentative of true LAA size. The objective of this study was to deter-
mine whether volume loading alters the left atrial appendage (LAA)
dimensions in patients undergoing percutaneous LAA closure.
METHODS Thirty-oneconsecutivepatientsundergoingpercutaneousLAA
closure who received volume loading during the procedure were included
in this study. After an overnight fast and induction of general anesthesia,
patients had their LAA dimensions (oriﬁce and depth) measured by trans-
esophageal echocardiography before and after 500-1000ml of intravenous
normal saline, aiming for a left atrial pressure >12mmHg.
RESULTS Successful implantation of LAA closure device was ach-
ieved in all patients. The average oriﬁce size of the LAA at baseline
was 20.5mm at 90 degrees, and 22.5mm at 135 degrees. Following
volume loading, the average oriﬁce size of the LAA increased to
22.5mm at 90 degrees, and 23.5mm at 135 degrees. The average in-
crease in oriﬁce was 1.9mm (p<0.0001). The depth of the LAA also
increased by an average of 2.5mm after volume loading (p<0.0001).
CONCLUSIONS Intraprocedural volume loading with saline increased
the LAA oriﬁce and depth dimensions during LAA closure. Operators
should consider optimizing the left atrial pressure with volume
loading before ﬁnal device sizing.
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BACKGROUND Left atrial (LA) appendage closure using Watchman
device was reported to be effective for atrial ﬁbrillation (AF) patients
to prevent stroke, systemic embolism, and cardiovascular death
compared with warfarin therapy. However, there are some cases with
thrombus formation in LA attached to Watchman device (Figure). In
this study, we investigated incidence, characteristics, and clinical
course of LA thrombus attached to Watchman device.
METHODS From June 2006 to March 2014, consecutive 119 AF patients
underwent the Watchman procedure in our institute. Transesophageal
echocardiographic (TEE) follow-upwas scheduled at 45 days, 6months,
and 12 months after procedure. The incidence of thrombus formation
attached to the device in TEE was evaluated. Furthermore, the patient
characteristics and clinical course were also investigated.
RESULTS Follow-up TEE identiﬁed LA thrombus attached to
Watchman device in 4 patients (3.4%). The prevalence of chronic AF
was signiﬁcantly higher in patients with thrombus than those without
thrombus (100% vs. 40.0%, p ¼ 0.03). Mean CHADS2 score tended to
be higher in patients with thrombus (3.8  0.6 vs. 2.5  0.1, p ¼ 0.06).
The thrombus type and anticoagulation status of each patient were
summarized in Table. Warfarin therapy was restarted or continued
after detection of the thrombus. The thrombus was disappeared in all
patients at subsequent follow-up TEE, and they can discontinue
warfarin therapy within 6 months after the detection of thrombus.The mean follow-up duration was 1456  546 days, and there were no
death, stroke, and systemic embolism events during the follow-up
period.
CONCLUSIONS Thrombus formation attached to Watchman device
can be observed especially in chronic AF patients with higher stroke
risk scores. Even after the detection of thrombus, short-term warfarin
therapy is effective and the clinical outcomes would be favorable.
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BACKGROUND There is limited data with WATCHMAN for left atrial
appendage (LAA) closure in patients with nonvalvular atrial ﬁbrilla-
tion (AF) and contraindications to anticoagulation. The purpose of
this study was to evaluate the safety and efﬁcacy of WATCHMAN in
our early Canadian experience.
METHODS We report our consecutive series of patients who under-
went WATCHMAN implantation at 4 Canadian centers (Vancouver
General Hospital, Montreal Heart Institute, Hamilton General Hospital
and Ottawa Heart Institute). Indications for LAA closure were
CHADS21, and contraindication/intolerance to or failure on anti-
coagulation. All cases were done under general anesthesia and
transesophageal echocardiography (TEE) guidance. Majority of pa-
tients received dual antiplatelet therapy (DAPT) for 3-6 months after
implant. Follow-up TEE was typically performed at 1-6 months post-
procedure.
RESULTS Ninety patients underwent LAA closure with WATCHMAN
from May 2013 to June 2015. The mean age was 75.0  7.9. The mean
CHADS2 score was 2.9  1.2, CHADS-VASc score was 4.4  1.5, and
HASBLED score was 3.2  1.2. Permanent AF was present in 66.7% and
paroxysmal AF in 33.3%. Indications for LAA closure were prior
bleeding in 81 patients (90.0%; 74 major bleeding, and 7 minor
bleeding), 9 were deemed high-risk for bleeding (renal failure,
cirrhosis, labile INR, esophageal ulcers, on DAPT), and 1 with recurrent
strokes on warfarin. Procedural success was 97.8% (88/90), with one
device embolization (snared percutaneously) and one implant failure
due to inadequate LAA depth. There was no procedural stroke/TIA,
death, MI, or cardiac tamponade. There were 3 major bleeding that
required transfusions. Mean hospital stay was 1.4  1.8 days. Antith-
rombotic therapy post-implant included DAPT in 66/90 (73.3%),
anticoagulant in 21/90 (5 warfarin, 16 direct anticoagulant), and
aspirin alone in 3/90. Follow-up TEE was available in 53 patients,
there was 1 device-associated thrombus (treated successfully with
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was 173.8  117.3 days, with no stroke or death, but there was 1 TIA
and 3 major bleeding.
CONCLUSIONS In our early Canadian experience, WATCHMAN for
LAA closure in patients contraindicated to anticoagulation is safe and
effective.
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BACKGROUND Percutaneous left atrial appendage (LAA) closure is
increasingly performed as an alternative to oral anticoagulation (OAC)
in patients with nonvalvular atrial ﬁbrillation (AF). We sought to
evaluate the cost-effectiveness of treating OAC contraindicated pa-
tients with the Amplatzer Cardiac Plug (ACP) device as compared to
aspirin alone.
METHODS A probabilistic patient-level Markov microsimulation
model with a lifetime horizon was performed to assess the discounted
lifetime costs, quality-adjusted life years (QALYs) and incremental
cost-effectiveness ratio of ACP compared to aspirin for AF patients
with contraindications to OAC. Baseline characteristics of the popu-
lation were based upon a published multi-center Canadian ACP
experience for patients at high stroke-risk (CHA2DS2-VASc) and OAC
contraindications. Clinical events included stroke, bleeding, myocar-
dial infarction, and procedure-related complications. Event-rates for
stroke and bleeding were based on the CHA2DS2-VASc and HASBLED
scores. The relative efﬁcacy of ACP and aspirin, as well as utility
scores, were obtained from the published literature. Canadian pro-
cedural and long-term costs were obtained from the Ontario Case
Costing Initiative and the Ontario Ministry of Health and Long Term
Care.
RESULTS Aspirin was less effective than LAA closure with ACP (4.26
 0.52 QALYs versus 4.69  0.33, respectively). The average dis-
counted lifetime cost was $30,830  11,726 for ACP and $39,751 
18,943 for aspirin. Thus, ACP was the dominant option, in that it was
both more effective and less expensive. Our results were robust with a
relatively modest degree of uncertainty, as ACP was the preferred
option in over 90% of simulations at a willingness-to-pay threshold of
$50,000 (ﬁgure).
CONCLUSIONS LAA closure is a novel stroke preventative therapy for
nonvalvular AF and is a cost-effective alternative to aspirin in patients
with contraindications to OAC.
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BACKGROUND Percutaneous left atrial appendage closure (LAAC) has
been although recognized as a new interventional routine, but the
clinical experience with large number of patients from single hospital
without cardiac surgery was worldwide very little. We evaluate pa-
tient selection, safety, feasibility, and midterm results of LAAC with
Watchman left atrial appendage (LAA) device in a single usual hos-
pital without onsite cardiac surgery backup.
METHODS A retrospective review of LAAC cases with Watchman
LAA device in our hospital between February 2012 and April 2015.
Demographic, echocardiographic, procedural, and clinical follow-up
data were collected and analyzed.
RESULTS LAAC was performed using Watchman device in 181 non-
valvular atrialﬁbrillation (NVAF)patientswith long-termoral anticoagulants
(OAC) contraindication. Mean age at closurewas 74.757.78 (range from 47-
92 years), 72.9% male. Hypertension, coronary artery disease, and diabetes
werepresent in71.9%,61.3%,and27.1%patients, respectively.MeanCHADS2
,CHA2DS-VASc and HASBLED scores were 2.21.1, 3.61.4 and 3.61.0,
respectively. Success rate of device implantation was 96.1% (93% in ﬁrst 90
cases, 99% in the second 91 cases) and associated with no major procedural
complications except one case of pericardial tamponade. Two Watchman
left atrial appendage devices were successful implanted in 3 cases due to
atypical anatomy of LAA. At least two transesophageal echocardiography
were performed in the ﬁrst 6 weeks and 6 months after LAAC, respectively.
Followupwas achieved in 92.5% patients and collected over amean follow-
up period of 266 days (range: 34 days to 3.0 years). No device related death
was recorded. At the most recent follow-up, almost all patients were
receiving antiplatelet therapy. Ischemic stroke/transient Ischemic attackwas
observed at an annual rate of 1.6% and the annual rate of any thromboem-
bolic (TE) event was 3.1%. Annual rate of major bleeding was 1.6%
CONCLUSIONS LAAC is a safe and effective stroke prevention therapy
in NVAF patients in a single usual hospital without onsite cardiac
surgery backup both at implantation and during short and midterm
follow-up periods and remarkable improvement of success rate can be
achieved with the increase of the experience of operators. A low
number of TE events was recorded during follow-up.
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BACKGROUND In left atrial appendage occlusion procedures, echo-
cardiography provides guidance for transseptal puncture, sizing and
device implantation and is utilized to assess occlusion grade. Most
cases of LAA closure are performed under general anesthesia and TEE
for guidance. ICE is used for guidance of interventional procedures,
however LAA visualization from the right atrium is often limited. The
aimof this studywas to assess the feasibility of LAAocclusion under ICE
guidance from the left atrium, conscious sedation and local anesthesia.
METHODS From October 2012 to June 2015, in one tertiary care center
in Montreal, 49 consecutive patients (mean age 758y) with AF and
long-term contraindication for anticoagulation underwent LAA
closure under local anesthesia, conscious sedation and ICE guidance
from the left atrium. The ICE catheter and device delivery sheaths
were advanced into the LA through separated ICE-guided transseptal
punctures. Baseline characteristics, procedural and follow-up data
were prospectively recorded. Procedural success was deﬁned as the
implantation of the closure device with adequate occlusion (grade 3
by angiography and<3 by ICE).
